FGF19 and FGF21: In NASH we trust.
Mol Metab
; 46: 101152, 2021 04.
Article
en En
| MEDLINE
| ID: mdl-33383173
ABSTRACT
OBJECTIVE:
FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development.METHODS:
We performed a detailed analyses of published preclinical and clinical data to offer insights into the mechanism of action, as well as PK/PD and efficacy data of the clinical assets.RESULTS:
Scouring the literature, we offer mechanistic insights from preclinical data using rodents and non-human primates and pharmacodynamic data from clinical studies.CONCLUSION:
The basic and applied science around endocrine FGFs has evolved exponentially over the years with FGF19 and FGF21 analogs are now entering Phase 3 clinical research.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Factores de Crecimiento de Fibroblastos
/
Enfermedad del Hígado Graso no Alcohólico
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Mol Metab
Año:
2021
Tipo del documento:
Article